Conti Francesco, Piscitelli Prisco, Italiano Giovanni, Parma Alessandro, Caffetti Maria Cristina, Giolli Lorenzo, Di Tanna Gian Luca, Guazzini Andrea, Brandi Maria Luisa
Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, "AO Sant'Andrea" Hospital, Rome, Italy.
Clin Cases Miner Bone Metab. 2012 Sep;9(3):157-60. Epub 2012 Dec 20.
The ADVICE (ADherence in VItamin-D and Calcium Embedded or not) survey was aimed to evaluate the effect of a patient-focused motivation strategy on the adherence to calcium and vitamin D supplementation. The survey also intended to identify possible factors being able to influence the compliance (i.e. the existence of individual preferences towards different dosages or regimens of supplementation).
We planned to involve consecutive patients visited between 2010 and 2011 at 35 centres specialized in diagnosis and treatment of osteoporosis in different Italian regions. Each patient has been requested to declare if he/she was already assuming any supplementation with calcium and vitamin D (naïve or not naïve). All patients underwent a first visit (T0) and two follow up visits at 6 and 12 months (T6 e T12). The assessment of the adherence was measured through the Morinsky Medication Adherence Scale, a score based on 8 different questions, specifically validated to determine therapeutical compliance (0-5: not acceptable; 6-7: acceptable; 8: ideal).
732 women (mean age: 66.9; average BMI: 25.3) and 30 men (mean age: 71.9; average BMI: 24.5) were enrolled; 34% of female patients (n=245) and 66% of males (n=20) reported previous fractures. Not naïve patients were 385 (54%). A total of 309 patients (43%) were concurrently assuming an antifracture drug; 229 subjects were osteoporotic (45%), while 224 were osteopenic (44%). The mean Morinsky score in not naïve patients was 5.72, 6.19 and 6.18 at T0, T6, and T12, respectively. Thus, no differences in the Morinsky score were observed between T6 and T12. Naïve patients showed an average Morinsky score of 5.78 at T6 and 6.39 at T12. Older age was not significantly associated with the observed changes in the scores. The onset of AEs related to the supplementation with calcium and vitamin D was able to negatively influence the adherence at the subsequent control point. Bone mineral density, previous fractures, and concurrent assumption of any antifracture drug did not significantly influence the adherence, as well as the differences in the dosages or regimens of calcium and vitamin D administration.
Activities aimed to strengthen motivation of the patients improved the adherence to calcium and vitamin D supplementations after only 6 months.
“ADVICE(维生素D和钙补充剂依从性与否)调查”旨在评估以患者为中心的激励策略对钙和维生素D补充剂依从性的影响。该调查还旨在确定可能影响依从性的因素(即对不同剂量或补充方案存在个体偏好)。
我们计划纳入2010年至2011年期间在意大利不同地区35家骨质疏松症诊断和治疗专科中心就诊的连续患者。每位患者被要求声明他/她是否已经在服用任何钙和维生素D补充剂(初治或非初治)。所有患者均接受了首次就诊(T0)以及6个月和12个月后的两次随访(T6和T12)。依从性评估通过Morinsky药物依从性量表进行测量,该量表基于8个不同问题打分,经过专门验证以确定治疗依从性(0 - 5分:不可接受;6 - 7分:可接受;8分:理想)。
共纳入732名女性(平均年龄:66.9岁;平均BMI:25.3)和30名男性(平均年龄:71.9岁;平均BMI:24.5);34%的女性患者(n = 245)和66%的男性患者(n = 20)报告有既往骨折史。非初治患者有385名(54%)。共有309名患者(43%)同时服用抗骨折药物;229名受试者患有骨质疏松症(45%),而224名患有骨量减少(44%)。非初治患者在T0、T6和T12时的平均Morinsky评分分别为5.72、6.19和6.18。因此,T6和T12之间的Morinsky评分未观察到差异。初治患者在T6时的平均Morinsky评分为5.78,在T12时为6.39。年龄较大与观察到的评分变化无显著相关性。与钙和维生素D补充剂相关的不良事件的发生能够对后续控制点的依从性产生负面影响。骨密度、既往骨折史以及同时服用任何抗骨折药物均未显著影响依从性,钙和维生素D给药剂量或方案的差异也未产生显著影响。
旨在增强患者积极性的活动在仅6个月后就提高了对钙和维生素D补充剂的依从性。